Table 2.
Univariate analysis of pelvic lymph node metastasis and clinicopathological features (N = 162).
| Lymph node metastasis | |||||
| Characteristic | N (%) | Negative (%) | Positive (%) | χ2 | P ∗ |
| Total | 162 (100) | 126 (77.8) | 36 (22.2) | ||
| Age (yr) | 1.309 | .253 | |||
| <45 | 26 (16.1) | 18 (69.2) | 8 (30.8) | ||
| ≥45 | 136 (83.9) | 108 (79.4) | 28 (20.6) | ||
| FIGO stage | .015$ | ||||
| IB1 | 119 (73.5) | 98 (82.4) | 21 (17.6) | ||
| IB2 | 8 (4.9) | 5 (62.5) | 3 (37.5) | ||
| IIA1 | 33 (20.4) | 23 (69.7) | 10 (30.3) | ||
| IIA2 | 2 (1.2) | 0 (0) | 2 (100) | ||
| Tumor diameter | .044$ | ||||
| ≤4 cm | 152 (93.8) | 121 (79.6) | 31 (20.4) | ||
| >4 cm | 10 (6.2) | 5 (50) | 5 (50) | ||
| Histological differentiation | 1.413 | .235 | |||
| G1 to 2 | 49 (30.2) | 41 (83.7) | 8 (16.3) | ||
| G3 | 113 (69.8) | 85 (75.2) | 28 (24.8) | ||
| Stromal infiltration | 10.436 | .005 | |||
| Superficial 1/3 | 25 (15.4) | 23 (92.0) | 2 (8.0) | ||
| Middle 1/3 | 49 (30.3) | 43 (87.8) | 6 (12.2) | ||
| Deep 1/3 | 88 (54.3) | 60 (68.2) | 28 (31.8) | ||
| SCC-Ag (ng/mL) | 14.339 | <.001 | |||
| <2.75 | 94 (58.0) | 83 (88.3) | 11 (11.7) | ||
| ≥2.75 | 68 (42.0) | 43 (63.2) | 25 (36.8) | ||
| Lymphovascular space invasion | 12.866 | <.001 | |||
| Negative | 48 (29.6) | 46 (95.8) | 2 (4.2) | ||
| Positive | 114 (70.4) | 80 (70.2) | 34 (29.8) | ||
| Parametrial involvement | 13.784 | <.001 | |||
| Negative | 153 (94.4) | 124 (81.0) | 29 (19.0) | ||
| Positive | 9 (5.6) | 2 (22.2) | 7 (77.8) | ||
| Vaginal residual | .214$ | ||||
| Negative | 158 (97.5) | 124 (78.5) | 34 (21.5) | ||
| Positive | 4 (2.5) | 2 (50) | 2 (50) | ||
FIGO = International Federation of Gynecology and Obstetrics, SCC-Ag = squamous cell carcinoma antigen.
∗
Pearson χ2 test.
$
Fisher exact test.